Psoriasis – Pipeline Review, H2 2018 | Pharma Drug Target | ResearchByMarkets

September 22, 2018/Press Release/ResearchByMarkets/— Psoriasis – Pipeline Review, H2 2018, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy. 

Report Highlights

Psoriasis – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The “Psoriasis” (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 14, 20, 40, 51, 122, 32 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 4 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/34689

Overview

– The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
– The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
– The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Why buy this report?

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Buy this report via Credit Card/Paypal or Wire Transfer:
https://www.researchbymarkets.com/paynow/34689

Companies Mentioned: 
3SBio Inc
AbbVie Inc
Abeome Corp
AbGenomics International Inc
Aclaris Therapeutics Inc
Adello Biologics LLC
Affibody AB
Alfacyte Ltd
Allergan Plc
Almirall SA
Alteogen Inc
Alvotech Iceland
Amgen Inc
AnaptysBio Inc
ApoPharma Inc
Aptevo Therapeutics Inc
Arbor Pharmaceuticals LLC
Arrien Pharmaceuticals LLC
AstraZeneca Plc
Athenex Inc
Atlantic Bio Sci LLC
Aurigene Discovery Technologies Ltd
Baliopharm AG
Bausch Health Companies Inc
Bayer AG
Beta Pharma Inc
BioApex sro
Biocad
Biocon Ltd
BioLingus AG
Bionovis SA
BirchBioMed Inc
Boehringer Ingelheim GmbH
Boston Pharmaceuticals Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
C4X Discovery Holdings PLC
CalciMedica Inc
Can-Fite BioPharma Ltd
Celgene Corp
Celon Pharma SA
ChemoCentryx Inc
ChironWells GmbH
Coherus BioSciences Inc
Compugen Ltd
Concenter BioPharma Silkim Ltd
Crescita Therapeutics Inc
Daiichi Sankyo Co Ltd
Dr. August Wolff GmbH & Co KG Arzneimittel
DURECT Corp
Eli Lilly and Co
ELORAC Inc
Escalier Biosciences BV
Evelo Biosciences Inc
Exicure Inc
Fresenius SE & Co KGaA
FunPep Co Ltd
FYB202 GmbH & Co KG
Galapagos NV
Galderma SA
Galectin Therapeutics Inc
Genentech Inc
GeneScience Pharmaceuticals Co Ltd
Genfit SA
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
GlycoMar Ltd
Grunenthal GmbH
Helix BioMedix Inc
HitGen LTD
Huabo Biopharm Co Ltd
Hualan Biological Engineering Inc
Hydra Biosciences Inc
iCo Therapeutics Inc
Immune Pharmaceuticals Inc
Immungenetics AG
Immunwork Inc
Innovation Pharmaceuticals Inc
Inspyr Therapeutics Inc
Instituto Biomar SA
Istesso Ltd
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadmon Corp LLC
Kaken Pharmaceutical Co Ltd
Kang Stem Biotech Co Ltd
Kv1.3 Therapeutics
Kymab Ltd
Lead Pharma Holding BV
LEO Pharma A/S
Link Health Group
Lupin Ltd
Lycera Corp
mAbxience SA
Maruho Co Ltd
Merck KGaA
Metrion Biosciences Ltd
MetrioPharm AG
Mitsubishi Tanabe Pharma Corp
Momenta Pharmaceuticals Inc
Mycenax Biotech Inc
Nanology LLC
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
Nordic Group BV
NovaLead Pharma Pvt Ltd
Novan Inc
Novartis AG
Nuevolution AB
Numab Innovation AG
Oncobiologics Inc
Orphagen Pharmaceuticals Inc
Pfizer Inc
Pharmedartis GmbH
Phenex Pharmaceuticals AG
Philogen SpA
PinCell srl
Pivot Pharmaceuticals Inc
Plant Advanced Technologies SA
Principia Biopharma Inc
Provectus Biopharmaceuticals Inc
Qilu Pharmaceutical Co Ltd
Realm Therapeutics Plc
Reata Pharmaceuticals Inc
RedHill Biopharma Ltd
Reliance Life Sciences Pvt Ltd
Samumed LLC
Sandoz International GmbH
Sareum Holdings Plc
SBI Biotech Co Ltd
selectION Inc
Shanghai Henlius Biotech Co Ltd
Shulov Innovative Science Ltd
Sienna Biopharmaceuticals Inc
Soligenix Inc
Spherium Biomed SL
sterna biologicals GmbH & Co KG
Sublimity Therapeutics Ltd
Sun Pharma Advanced Research Company Ltd
Syntrix Biosystems Inc
Tasly Pharmaceutical Group Co Ltd
TheraMAB LLC
Tolero Pharmaceuticals Inc
Torrent Pharmaceuticals Ltd
UCB SA
Vicore Pharma AB
Visionary Pharmaceuticals Inc
vTv Therapeutics Inc
Wellstat Therapeutics Corp
XBiotech Inc
Yuhan Corp
Zai Lab Ltd
Zhejiang Hisun Pharmaceutical Co Ltd

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.